Skip to main content

IB10 sphingotest® Troponin-99


IB10 sphingotest® Troponin-99 is a rapid point-of-care (POC) immunoassay for the quantitative in vitro determination of Cardiac Troponin I (cTnI) in human Lithium-Heparin whole blood and plasma.

The test is designed for professional use only and may be used on sites where near patient testing is practiced.

Cat No. IVR-IB50 | Troponin I (package of 10 discs)

Clinical Significance

cTnI determination aids in the diagnosis of myocardial infarction (MI) (1,2) and patients with non-ST-segment elevation (NSTEMI) acute coronary syndrome (ACS) (3,4). Elevated cTnI levels in the NSTEMI ACS sub-population correlate with the relative risk of mortality, MI or increased probability of ischemic events requiring urgent revascularization procedures. For patients with chronic or acute decompensated heart failure (HF), measurements of cTnI provide complementary information to assist in patient evaluation and management.

Expected Values

From a population of 224 individuals, the IB10 sphingotest® Troponin-99 test was used to determine the concentration upper reference limits of cTnI. This population included apparently healthy individuals.

Upper Reference Limit: 

The 99th percentile upper reference limit is 0.10 ng/mL. Each laboratory should establish a reference range that represents the patient population that is to be evaluated at their facility.


 

Whole Blood vs. Plasma Comparison

All our assays correlate with r=0.9. For more detailed information please read the IFUs or connect with our sales representatives.

 


 

Key Features

Easy Handling
Sample TypeLithium-Heparin whole blood and plasma samples
Time to Result20 minutes
Measuring Range0.05 - 30 ng/mL
Limit of Detection0.05 ng/mL
No High Dose Hook Effectup to 500 ng/mL
Analyte Stability for IB10 Measurement48 hours for whole blood

 

Request a quote

IB10 sphingotest® Troponin-99 is a rapid point-of-care (POC) immunoassay for the in vitro quantitative determination of Cardiac Troponin I.

Request a Quote


References

(1) Reichlin T et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011; 124:136–145.

(2) Thygesen K et al. Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95.

(3) Babuin L et al. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005 Nov 8;173(10):1191-202.

(4) Larue C et al. Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction. Clin Chem. 1993 Jun;39(6):972-9.